LRRK2 — Leucine Rich Repeat Kinase 2

Overview

Lrrk2 — Leucine Rich Repeat Kinase 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

LRRK2 (Leucine-Rich Repeat Kinase 2), also known as dardarin, is a large multi-domain protein kinase encoded by the LRRK2 gene on chromosome 12q12^{2Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease2004 · Neuron · PMID 15541308Open reference}. It is one of the most common genetic causes of Parkinson’s disease (PD), with pathogenic mutations accounting for approximately 5-10% of familial PD cases and 1-3% of sporadic PD cases^{3The role of LRRK2 in Parkinson's disease2023 · Nat Rev Neurosci · DOI 10.1038/s41583-023-00712-xOpen reference}. The LRRK2 protein is a member of the ROCO family of Ras-of-Complex (ROC) proteins and possesses both kinase and GTPase activity.

The discovery of LRRK2 mutations as a cause of PARK8-linked Parkinson’s disease in 2004 marked a major breakthrough in understanding the genetics of PD and has led to extensive research into its function and therapeutic targeting^{1Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology2004 · Neuron · PMID 15541309Open reference4LRRK2 kinase in Parkinson's disease2018 · Science · DOI 10.1126/science.aar5689Open reference}.

Structure

AlphaFold DB provides a full-length predicted structure for LRRK2 (UniProt Q5S007, model v6) with mean pLDDT 77.5. View the model at AlphaFold DB or download the PDB file.

Domain and region confidence from per-residue pLDDT:

• Residues 1-969 (Required for RAB29-mediated activation): mean pLDDT 72.6 (confident).

• Residues 319-348 (Coiled coil): mean pLDDT 51.1 (low).

• Residues 1328-1511 (Roc): mean pLDDT 78.7 (confident).

• Residues 1546-1740 (COR): mean pLDDT 76.8 (confident).

• Residues 1879-2138 (Protein kinase): mean pLDDT 80.3 (confident).

• Residues 2139-2183 (WD 1): mean pLDDT 81.0 (confident).

• Residues 2281-2327 (WD 4): mean pLDDT 83.8 (confident).

• Residues 2443-2497 (WD 7): mean pLDDT 75.8 (confident).

Overall confidence distribution: 345 residues (14%) very high, 1659 residues (66%) confident, 302 residues (12%) low, 221 residues (9%) very low. Low or very-low pLDDT segments should be interpreted as flexible or disordered regions rather than resolved binding pockets.

UniProt function annotation: Serine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed:17114044, PubMed:20949042, PubMed:21850687, PubMed:22012985, PubMed:23395371, PubMed:24687852, PubMed:25201882, PubMed:26014385, PubMed:26824392. Subcellular localization: Cytoplasmic vesicle, Perikaryon, Golgi apparatus membrane, Cell projection, axon, Cell projection, dendrite, Endoplasmic reticulum membrane, Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane, Endosome. Curated disease associations include: Parkinson disease 8.

Normal Function

Under physiological conditions, LRRK2 participates in multiple cellular processes:

Cellular Signaling

LRRK2 acts as a molecular scaffold for various signaling pathways:

• MAPK signaling: Modulates ERK, JNK, and p38 pathways

• Wnt signaling: Interacts with β-catenin pathway components

• mTOR signaling: Regulates autophagy and cell growth

Cytoskeletal Functions

• Actin cytoskeleton: Regulates actin dynamics and cell morphology

• Microtubule function: Associates with microtubules, affects transport

• Neurite outgrowth: Promotes neuronal process extension

Membrane Trafficking

• Endocytosis: Regulates vesicle trafficking and receptor internalization

• Lysosomal function: Involved in autophagy-lysosome pathway

• Synaptic transmission: Modulates synaptic vesicle release

Inflammation

• Microglial activation: Regulates inflammatory responses

• Cytokine production: Affects neuroinflammation in PD^{5LRRK2 in Parkinson disease: Challenges of clinical trials2022 · Nat Rev Neurol · DOI 10.1038/s41582-022-00708-6Open reference}

Tissue Expression

LRRK2 is widely expressed with highest levels in:

• Brain: Striatum, cerebral cortex, hippocampus, cerebellum

• Peripheral organs: Kidney, lungs, lymph nodes

• Immune cells: Monocytes, macrophages, B-cells

Pathogenesis in Parkinson’s Disease

Genetic Evidence

LRRK2 mutations are the most common known genetic cause of PD:

• G2019S: Most common pathogenic mutation (~5% familial, ~1% sporadic)

  • Located in kinase domain activation loop

  • Increases kinase activity by 2-3 fold

  • Penetrance: ~70% by age 80

• R1441C/G/H: Located in ROC domain

  • Reduces GTPase activity

  • Causes constitutive activation

• Y1699C: Located in COR domain

  • Impairs dimerization

  • Increases kinase activity

• I2020T: Located in kinase domain

  • Increases autophosphorylation

Mechanisms of Neurodegeneration

LRRK2 mutations cause neuronal dysfunction through several mechanisms:

1. Kinase hyperactivity: Enhanced phosphorylation of substrates

2. Dysregulated GTPase activity: Impaired ROC domain function

3. Mitochondrial dysfunction: Altered mitochondrial dynamics

4. Autophagy impairment: Defective lysosomal degradation

5. Synaptic dysfunction: Altered neurotransmitter release

6. Neuroinflammation: Microglial activation

Substrate Phosphorylation

Key LRRK2 substrates include:

• Rab proteins (Rab3, Rab5, Rab7, Rab10, Rab12): Vesicle trafficking

• MAP1B: Microtubule-associated protein

• ERK1/2: Cell signaling

• Tau: Microtubule stability

• α-Synuclein: Aggregation modulation

Recent Research Updates (2025-2026)

Recent studies have advanced our understanding of LRRK2 function and its role in Parkinson’s disease:

• LRRK2-mediated pyroptosis: Research demonstrates that LRRK2 mediates pyroptosis via the NLRP3/Caspase-1/GSDMD pathway in Parkinson’s disease progression^{2Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease2004 · Neuron · PMID 15541308Open reference}.

Therapeutic Targeting

LRRK2 represents one of the most promising therapeutic targets in PD drug development:

Kinase Inhibitors

Multiple LRRK2 inhibitors are in clinical development:

• DNL151/DNL312: Denali Therapeutics - Phase 1/2 trials

• BIIB122 (DNL151): Biogen partnership - Phase 1b

• PF-06649751: Pfizer - Phase 1

• GZ-161: Gains in preclinical models

These inhibitors aim to:

• Reduce kinase activity to normal levels

• Prevent neurodegeneration

• Potentially reverse pathology

Challenges

• Peripheral toxicity: Kidney and lung side effects

• Blood-brain barrier penetration: Required for CNS effect

• Biomarkers: Need for patient selection

• Genetic complexity: Variable penetrance

Other Therapeutic Approaches

• Antisense oligonucleotides: Gene silencing approaches

• Protein-protein interaction inhibitors: Block pathogenic interactions

• GTPase activators: Enhance ROC domain function

Gene Therapy Approaches

Gene therapy for LRRK2-associated neurodegeneration represents a promising frontier for disease modification. Unlike small molecule inhibitors that require chronic dosing and may have peripheral toxicity, gene therapy approaches aim to provide durable, potentially curative treatment by directly addressing the genetic basis of the disease.

Antisense Oligonucleotides (ASOs)

Antisense oligonucleotides are single-stranded DNA sequences that bind to complementary mRNA, preventing translation or promoting degradation:

• Mechanism: ASOs bind to LRRK2 mRNA, reducing protein translation through RNase H-mediated cleavage

• Advantages: Sequence-specific targeting, can reduce LRRK2 expression without affecting other kinases

• Challenges: Blood-brain barrier penetration, delivery to target neurons, dosing frequency

• Current status: Preclinical development, with promising results in mouse models showing reduced LRRK2 expression and improved phenotypes

• Delivery methods: Intrathecal injection, convection-enhanced delivery

RNA Interference (RNAi)

RNAi uses small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) to silence gene expression:

• Viral-delivered shRNA: AAV vectors carrying shRNA cassettes targeting LRRK2

• Target regions: 5’ UTR and coding sequences to maximize knockdown

• Efficacy: Up to 80% reduction of LRRK2 expression in preclinical models

• Considerations: Off-target effects, immune response to viral delivery

CRISPR-Based Gene Editing

Gene editing technologies offer the potential to directly correct pathogenic mutations:

• Base editing: Precise single-nucleotide changes without double-strand breaks

• Prime editing: Insertions, deletions, and replacements

• AAV-delivered Cas9: System for in vivo editing of neurons

• Challenges: Efficiency of editing in post-mitotic neurons, delivery to specific brain regions

• Future potential: Mutation-specific correction for patients with LRRK2 kinase-activating mutations

Viral Vector Delivery Systems

Gene Therapy for Atypical Parkinsonism

LRRK2 mutations have been identified in patients with atypical parkinsonian syndromes, including:

• Multiple System Atrophy (MSA): LRRK2 variants may modify disease severity and progression

• Progressive Supranuclear Palsy (PSP): Some LRRK2 mutations associated with PSP phenotypes

• Corticobasal Syndrome (CBS): Rare LRRK2 variants reported in CBS patients

Gene therapy approaches may benefit these patient populations by:

1. Reducing mutant LRRK2 expression

2. Normalizing kinase activity

3. Protecting against neurodegeneration

Current Research Status

While most LRRK2 gene therapy development has focused on classic Parkinson’s disease, emerging research addresses atypical parkinsonism:

• Preclinical models: LRRK2 knockout and knockdown approaches show neuroprotection in models relevant to MSA and PSP pathology

• AAV-mediated delivery: Studies using AAV vectors to deliver shRNA or ASOs targeting LRRK2 demonstrate efficient CNS transduction in non-human primates

• Therapeutic window: Gene therapy may provide benefit even after symptom onset, as LRRK2 hyperactivity continues to drive pathology

Clinical Trial Considerations for Atypical Parkinsonism

Future Directions

• Mutation-specific approaches: Base editing or prime editing to correct specific pathogenic mutations

• Combination therapies: Gene therapy combined with small molecule kinase inhibitors

• Patient stratification: Genetic testing to identify LRRK2 carriers within atypical parkinsonism populations

Key Publications

1. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601-607. ^{1Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology2004 · Neuron · PMID 15541309Open reference}(https://pubmed.ncbi.nlm.nih.gov/15541309/)

2. Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44(4):595-600. ^{2Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease2004 · Neuron · PMID 15541308Open reference}(https://pubmed.ncbi.nlm.nih.gov/15541308/)

3. Cookson MR. The role of LRRK2 in Parkinson’s disease. Nat Rev Neurosci. 2023;24(7):425-442.

4. Watterson GR, Saito M, Kanyo JE, et al. LRRK2: Kinase, GTPase, and scaffolding functions. Mov Disord. 2023;38(5):742-755.

5. Alessi DR, Sammler E. LRRK2 kinase in Parkinson’s disease. Science. 2018;361(6405):1172-1178.

6. Tolosa E, Vila M. LRRK2 in Parkinson disease: Challenges of clinical trials. Nat Rev Neurol. 2022;18(11):651-663.

See Also

• Parkinson’s Disease

• LRRK2 Kinase Inhibitors

• Dopaminergic Neurons

• Kinase Signaling Pathways

External Links

• NCBI Gene: https://www.ncbi.nlm.nih.gov/gene/120892

• Ensembl: https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188906

• OMIM: https://omim.org/entry/609007

• UniProt: https://www.uniprot.org/uniprot/Q5S007

• LRRK2 Consortium: https://www.lrrk2.org

• Michael J. Fox Foundation: LRRK2 Research

• Allen Human Brain Atlas: Expression data for LRRK2

• Allen Cell Type Atlas: Cell type expression data

• BrainSpan Atlas: Developmental transcriptome data

Pathogenic LRRK2 Mutations

LRRK2 Therapeutic Target Comparison

LRRK2 Pathway in Parkinson’s Disease

flowchart TD
    subgraph LRRK2_Biology
        A["LRRK2 Gene<br/>(12q12)"]:::blue --> B["LRRK2 Protein<br/>(2527 aa)"]:::blue
        B --> C["ROC GTPase<br/>Domain"]:::orange
        B --> D["COR Dimerization<br/>Domain"]:::orange
        B --> E["Kinase Domain<br/>(MAPKKK)"]:::purple
    end

    subgraph Kinase_Activity
        E --> F["Rab Substrate<br/>Phosphorylation<br/>Rab3,5,7,10"]:::orange
        F --> G["Vesicle Trafficking<br/>Regulation"]:::green
        E --> H["Tau<br/>Phosphorylation"]:::red
        E --> I["Alpha-Synuclein<br/>Modulation"]:::red
    end

    subgraph Signaling_Pathways
        B --> J["MAPK/Wnt/mTOR<br/>Signaling"]:::orange
        C --> K["GTP Hydrolysis"]:::orange
        K --> L["Kinase Activity<br/>Regulation"]:::purple
    end

    subgraph Pathological_Outcomes
        G --> M["Autophagy-Lysosome<br/>Pathway Dysfunction"]:::red
        I --> N["Protein<br/>Aggregation"]:::red
        H --> N
        N --> O["Neurodegeneration"]:::red
        M --> O
    end

    classDef blue fill:#0a1929,stroke:#333
    classDef orange fill:#3e2200,stroke:#333
    classDef purple fill:#1a0a1f,stroke:#333
    classDef green fill:#0e2e10,stroke:#333
    classDef red fill:#3b1114,stroke:#333

    click A "/genes/lrrk2" "LRRK2 Gene"
    click B "/proteins/lrrk2-protein" "LRRK2 Protein"
    click C "/mechanisms/rocp-co-domain" "ROC GTPase Domain"
    click E "/mechanisms/lrrk2-pathway" "LRRK2 Kinase Pathway"
    click F "/mechanisms/rab-gtpase-signaling" "Rab GTPase Signaling"
    click G "/mechanisms/lysosome-dysfunction" "Lysosome Dysfunction"
    click H "/mechanisms/tau-pathology" "Tau Pathology"
    click I "/proteins/alpha-synuclein" "Alpha-Synuclein"
    click N "/mechanisms/synucleinopathy" "Synucleinopathy"
    click O "/diseases/parkinsons-disease" "Parkinson's Disease"

Upcoming Conferences

MDS 2026

The MDS International Congress 2026 will be held October 4-8, 2026 in Seoul, Korea. See MDS 2026 — Parkinson’s Disease Sessions for coverage of LRRK2 research presentations expected at the congress.

Allen Brain Atlas Data

Gene Expression

LRRK2 (Leucine-Rich Repeat Kinase 2) expression patterns:

• Substantia nigra - High expression in dopaminergic neurons

• Cerebral cortex - Layer 5 pyramidal neurons

• Hippocampus - CA1 and dentate gyrus neurons

• Kidney - High expression in renal tubules (also relevant for LRRK2 inhibitor side effects)

Single-Cell Expression

LRRK2 is expressed in:

• Dopaminergic neurons (TH+, SLC6A3+)

• Pyramidal neurons (SLC17A7+)

• Certain interneuron populations

• Microglia (at lower levels)

Brain Region Expression Levels

Clinical Genetics

Mutation Spectrum

LRRK2 mutations account for approximately 5-10% of sporadic PD and up to 40% of familial cases in some populations:

Common pathogenic mutations:

• G2019S (most common, ~5% of PD)

• R1441C/G/H

• Y1699C

• I2020T

Risk variants:

• G2385R (Asian populations)

• R1628P (Asian populations)

Genotype-Phenotype Correlations

• G2019S: Typical PD phenotype, earlier onset

• R1441 mutations: More variable phenotype

• Complex phenotypes: May include dementia

Genetic Testing

• Diagnostic testing: Available for at-risk individuals

• Predictive testing: Controversial in asymptomatic carriers

• Family screening: Recommended for at-risk family members

Therapeutic Development

Kinase Inhibitors

Several LRRK2 inhibitors in development:

• DNL151: Phase 3 trials

• DNL312: Preclinical

• LT-647: Preclinical

• PF-06447475: Phase 1/2

Gene Therapy Approaches

• ASO therapy: Target mutant transcript

• CRISPR editing: Correct pathogenic mutations

• AAV delivery: Express therapeutic constructs

Immunomodulatory Strategies

LRRK2 inhibitors may benefit through:

• Microglial modulation: Reduce neuroinflammation

• T-cell regulation: Alter adaptive immune responses

• Peripheral effects: Systemic immunomodulation

Biomarkers

Fluid Biomarkers

• CSF LRRK2: Kinase activity levels

• Blood cells: LRRK2 expression and activity

• Exosomes: Cargo containing LRRK2

Imaging Biomarkers

• DAT imaging: Dopaminergic integrity

• MRI: Structural changes

• PET: Glucose metabolism

Research Directions

Unanswered Questions

• What is the normal physiological function of LRRK2?

• How do mutations lead to neurodegeneration?

• What is the optimal therapeutic target?

• Can biomarkers predict treatment response?

Clinical Trials

• Multiple Phase 1/2 trials of kinase inhibitors

• Gene therapy approaches in preclinical development

• Immunotherapy strategies in planning

Gene-Environment Interactions

LRRK2 variants significantly modify the risk associated with environmental exposures, representing a critical area of PD etiology research.

Pesticide Exposure

The strongest gene-environment interaction evidence involves LRRK2 and pesticide exposure:

• Synergistic Risk: LRRK2 G2019S carriers exposed to pesticides have 2-3x higher PD risk than expected from additive effects

• Biological Mechanism: Both pesticide exposure and LRRK2 mutations impair the autophagy-lysosome pathway

• Dose-Response: Risk increases with duration and intensity of pesticide exposure

Industrial Solvents

LRRK2 variants modify risk associated with:

• Trichloroethylene (TCE): Organic solvent exposure shows stronger association in LRRK2 carriers

• Perchloroethylene (PCE): Dry cleaning chemical exposure

• Mechanism: Both LRRK2 dysfunction and solvent exposure impair mitochondrial function

Heavy Metals

• Manganese exposure: LRRK2 carriers show heightened susceptibility to metal-induced parkinsonism

• Lead exposure: Modified risk in carriers of kinase-activating variants

• Copper: Altered homeostasis in LRRK2 mutation carriers

Air Pollution

• PM2.5 exposure: LRRK2 carriers show stronger association with particulate matter exposure

• Mechanism: Both air pollution and LRRK2 dysfunction impair lysosomal function

Prevention Implications

For LRRK2 carriers:

1. Occupational Safety: Minimize pesticide and solvent exposure

2. Environmental Protection: Air filtration in high-pollution areas

3. Heavy Metal Avoidance: Occupational screening and protective equipment

4. Regular Monitoring: Neurological assessment for early detection

See MDS 2026 — GBA and LRRK2 Genetic Susceptibility for comprehensive coverage.